Related Experiment Video
Updated: Feb 18, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
A Novel Heat Shock Protein 70-based Vaccine Prepared from DC-Tumor Fusion Cells
Desheng Weng1, Stuart K Calderwood2, Jianlin Gong3
1Department of Medicine, Boston University School of Medicine, Boston, MA, 02118, USA.
Abstract:
We have developed an enhanced molecular chaperone-based vaccine through rapid isolation of Hsp70 peptide complexes after the fusion of tumor and dendritic cells (Hsp70.PC-F). In this approach, the tumor antigens are introduced into the antigen processing machinery of dendritic cells through the cell fusion process and thus we can obtain antigenic tumor peptides or their intermediates that have been processed by dendritic cells. Our results show that Hsp70.PC-F has increased immunogenicity compared to preparations from tumor cells alone and therefore constitutes an improved formulation of chaperone protein-based tumor vaccine.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Vaccinations

